Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Trials & Filings in Brief: Jan. 7, 2014 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances, Trials & Filings

Trials & Filings in Brief: Jan. 7, 2014

Alitair, Celgene, Erytech, Galena, Neurocrine, Orexigen, Shield, TeaRx

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase II
Erytech to begin pancreatic cancer study . . . read more

Galena enrolls first ovarian cancer patient . . . read more

Neurocrine Biosciences posts positive results in tardive dyskinesia . . . read more

TeaRx begins anticoagulant trial . . . read more

Phase III
Positive results for Shield’s IDA treatment in IBD . . . read more

Approvals
Celgene’s Abraxane approved in EU for pancreatic cancer . . . read more

Filings
Alitair gets orphan status for bronchiectasis treatment . . . read more

Orexigen gets Contrave PDUFA date . . . read more

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics